News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Johanna Bendell, MD, Sarah Cannon Cancer Institute

Articles by Johanna Bendell, MD, Sarah Cannon Cancer Institute

Applying Data to the Real World in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Emerging Approaches in HER2+ Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

VEGFR TKIs in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Maintenance Therapy in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Adjuvant Treatment in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Looking Toward the Future in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Toxicity Management in Second Line for Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Clinical Rationale for Antiangiogenics in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Predicting Response With Biomarkers in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Applying New Data in the Real-World for GEJ Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

ESMO 2020: Practice-Changing Data in Esophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

First-Line I/O Successful in Gastric Adenocarcinoma

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Frontline Treatment in Metastatic Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Optimal Approach Toward Advanced Gastric Cancers in US

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Global Trends in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Latest Updated Articles

ESMO 2020: Practice-Changing Data in Esophageal Cancer
Published: October 22nd 2020 | Updated:
First-Line I/O Successful in Gastric Adenocarcinoma
Published: October 22nd 2020 | Updated:
Predicting Response With Biomarkers in Gastric Cancers
Published: October 22nd 2020 | Updated:
Optimal Approach Toward Advanced Gastric Cancers in US
Published: October 22nd 2020 | Updated:
Treatment Landscape in Gastric Cancers Pre-ESMO 2020
Published: October 22nd 2020 | Updated:
Applying New Data in the Real-World for GEJ Cancer
Published: October 22nd 2020 | Updated:

Trending on OncLive

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL